Home  >  TopNews
 Premier Research India
you can get e-magazine links on WhatsApp. Click here
+ Font Resize -

Indian pharma market clocks growth of 8.7% in Aug 2018 to Rs.11,342 crore

Our Bureau, Mumbai
Tuesday, September 11, 2018, 08:00 Hrs  [IST]

The Indian Pharmaceutical Market (IPM) has shown slower monthly growth of 8.7 per cent during August 2018 and reached at Rs.11,343 crore as compare to July 2018. According to AIOCD Awacs report, the volumes have slowed down considerably. FDC related market showed growth of 2.2 per cent while the non-FDC market shown a growth of 8.9 per cent. The single molecules grew at 8.7 per cent. MNCs achieved growth of 6.6 per cent in August 2018, while Indian companies grew faster at 9.2 per cent. In the non-NLEM category, Indian companies showed a growth of 7.5 per cent, whereas MNCs grew at 9.8 per cent.

Among the top 10 corporate, Intas has the highest growth in 13.6 per cent followed by Lupin at 13.4 per cent and Torrent at 10.8 per cent. 46 corporate showing positive growth of IPM. from top 50 companies. Sun portfolio has shown a growth of 5 per cent, while Ranbaxy growing faster of 6.2 per cent. Emcure moved up by 9.9 per cent and Zuventus increased by 10.4 per cent during August 2018. Among the top 60 MNCs, Boehringer Ingelheim is the fastest growing at 33.5 per cent followed by Bayer at 33.3 per cent and AstraZeneca at 22.9 per cent.

Total 14 new companies launched in last 36 months and 2 companies cross sales of over Rs.10 crore. From therapy perspective 17 therapies are showing a positive growth for the month of August 2018. Respiratory market posted a single growth of 5.8 per cent, gastro intestinal showed a double digit growth of 10.8 per cent and pain and analgesic moved up by 6.9 per cent. The Chronic therapies like anti-diabetic increased by 14 per cent, followed by cardio by 12.5 per cent and CNS by 8.9 per cent. Anti infectives has shown a growth of 4 per cent while VMS market is growing at 9 per cent. Derma is growing at double digit of 10.2 per cent in August 2018.

From the regional perspective 29 regions have posted positive growth for the month of August 2018. Punjab market grew at the highest rate of 20.9 per cent followed by South Maharashtra growing at 19.5 per cent and North Maharashtra at 18.1 per cent.

Amoxycillin plus clavulanic acid market achieved growth of 10.4 per cent to Rs.181.5 crore and 18 glimepiride plus metmformin market moved up by 8.1 per cent at Rs.188.4 crore. Azilsartan plain market is valued at Rs.70.4 crore on MAT basis and sofosbuvir and its combination market has reached at Rs.705.4 crore. The luliconazole market reached at Rs.343.2 crore while tenegliptin and its combination market valued at Rs.760.8 crore. The market of paracetamol plain stagnant with a growth rate of 0.6 per cent on monthly basis, plain atorvastatin has posted a growth of 3 per cent. Probiotic microbes is showing a double digit growth of 19.6 per cent.

Maxtard brand posted monthly sales worth Rs.44 crore while spasmoproxivon plus has registered sales of Rs.39 crore. Glycomet GP is at Rs.40 crore, Lantus is at Rs.35 crore and Galvus Met at 34 crore. Liv 52 brand touched to Rs.27 crore and Janumet at Rs.36 crore. Further, Augmentin reached at Rs.33 crore during August 2018.

Azilsartan and combinations are now valued at Rs.75.1 crore. On MAT basis with Abel (Lupin) leading followed by Zilarbi (Emcure) and Aztric (Intas). Luliconazole segment reached at Rs.343.2 crore and there are already 60 new brands launched in the segment.


Post Your commentsPOST YOUR COMMENT
* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |